Kestra CEO’s Insider Sales: What Investors Should Know
Explore how Kestra Medical’s CEO’s Rule 10b‑5‑1 insider sales—15k shares at $25‑27—impact liquidity, regulatory risk, and investor sentiment in the competitive cardiac‑device market.
4 minutes to read